Inspiration Healthcare Group PLC EC certificates extended to May 2024
21 Gennaio 2020 - 8:01AM
RNS Non-Regulatory
TIDMIHC
Inspiration Healthcare Group PLC
21 January 2020
Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")
Inspiration Healthcare
EC certificates extended to May 2024
As part of Inspiration Healthcare's preparation for the new
European Union Medical Device Regulation (MDR) which comes into
force in May 2020, the Company confirms that it has now received
its new EC Certificate for its products (excluding the recently
acquired Viomedex products) to extend until May 2024 their CE
marking under the existing Medical Device Directive.
As a result, all Inspiration Healthcare's products will not be
adversely affected by the implementation of MDR. The Company can
continue to promote the products where a valid EC Certificate is
accepted whilst it applies to its Notified Body (TÜV SÜD) to review
its technical documentation under the new regulation.
Commenting today, Neil Campbell, Inspiration Healthcare's Chief
Executive said:
"We are pleased to have extended the EC Certificate which allows
us to continue to promote the products whilst we review our
technical documentation and apply for conformity to the new Medical
Device Regulation. Our new and innovative products in our R&D
pipeline are already being developed with MDR in mind and we expect
a seamless transition to the MDR in due course."
Enquiries:
Inspiration Healthcare Tel: 01455 840555
Group plc
Neil Campbell, Chief Executive
Officer
Mike Briant, Chief Financial
Officer
Nominated Adviser & Broker Tel: 0207 397 8900
Cenkos Securities plc
Stephen Keys
Mark Connelly
Cameron MacRitchie
Cadogan PR Tel: 07771 713608
Alex Walters
alex.walters@cadoganpr.com
About Inspiration Healthcare
Inspiration Healthcare (AIM: IHC) is a global provider of
medical technology for use in critical care & operating
theatres. The Company provides high quality innovative products to
patients around the world which help to improve patient outcomes
and it actively invests in innovative product opportunities and
disruptive technologies.
Through investment in research and development the Company has 6
key own brand products that can be used within the first 6 hours of
life to help premature and sick babies; helping with assessment,
resuscitation, stabilisation as well as preventing brain damage.
Additionally the Company has its own range of products for
maintaining normothermia pre- during and post-surgery.
With product availability extending to over 50 countries through
a distribution network, Inspiration Healthcare's success has been
built on continuous innovation, excellent customer service and an
inherent commitment to improving patient outcomes, working in close
collaboration with key opinion leaders across the globe.
In the UK and Ireland the Company has a direct sales team
selling Inspiration Branded and complementary products from third
parties, with an additional range of home healthcare products. This
is supported by Technical Support for planned preventative
maintenance and emergency assistance.
Further information on Inspiration Healthcare can be seen at
www.inspiration-healthcare.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFLFLDLRIIFII
(END) Dow Jones Newswires
January 21, 2020 02:01 ET (07:01 GMT)
Grafico Azioni Inspiration Healthcare (LSE:IHC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Inspiration Healthcare (LSE:IHC)
Storico
Da Apr 2023 a Apr 2024